Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025

Ideaya Biosciences (IDYA) and Jiangsu Hengrui Pharmaceuticals Co. announced the publication of an abstract for an oral presentation on IDE849 at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place September 6-9 in Barcelona, Spain. The presentation will cover efficacy and safety results in SCLC from the Phase 1 trial Hengrui is conducting in China for IDE849, a potential first-in-class delta-like ligand 3-targeting Topoisomerase-1 payload antibody drug conjugate. “We are excited to have the first-in-human Phase 1 clinical efficacy and safety data presented by our partner Hengrui for IDE849 in SCLC patients at the WCLC 2025, as IDEAYA rapidly advances the global development of IDE849. IDE849 represents a potential first-in-class DLL3-TOP1 ADC, and we look forward to evaluating its clinical potential as both a monotherapy agent in SCLC and NET patients, as well as in combination with immunotherapy and our Phase 1 PARG inhibitor, IDE161,” said representatives of Ideaya.